Company Description
NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States.
It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions.
It also developing NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment.
In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Lumagel Beauty, Kenkoderm and Silly George brand names.
The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019.
NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.
| Country | United States |
| Founded | 1997 |
| IPO Date | Dec 22, 2021 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Adam Levy |
Contact Details
Address: 2150 Cabot Boulevard West, Suite B Langhorne, Pennsylvania 19047 United States | |
| Phone | 215 702 8550 |
| Website | nexgel.com |
Stock Details
| Ticker Symbol | NXGL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.50 |
| CIK Code | 0001468929 |
| CUSIP Number | 65344E107 |
| ISIN Number | US65344E1073 |
| Employer ID | 26-4042544 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Adam R. Levy | Chief Executive Officer, President and Director |
| Joseph F. McGuire | Chief Financial Officer |
| Gregory Robb | Vice President of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 14, 2025 | 8-K | Current Report |
| Jun 20, 2025 | 8-K | Current Report |
| Jun 4, 2025 | 8-K | Current Report |
| May 16, 2025 | 144 | Filing |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2025 | 144 | Filing |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 25, 2025 | 8-K | Current Report |